These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 35831042)
21. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial. Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843 [TBL] [Abstract][Full Text] [Related]
22. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022. Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491 [TBL] [Abstract][Full Text] [Related]
23. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study. Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173 [TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis. Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
27. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M BMJ; 2021 May; 373():n1088. PubMed ID: 33985964 [TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. Schuh AJ; Satheshkumar PS; Dietz S; Bull-Otterson L; Charles M; Edens C; Jones JM; Bajema KL; Clarke KEN; McDonald LC; Patel S; Cuffe K; Thornburg NJ; Schiffer J; Chun K; Bastidas M; Fernando M; Petropoulos CJ; Wrin T; Cai S; Adcock D; Sesok-Pizzini D; Letovsky S; Fry AM; Hall AJ; Gundlapalli AV Microbiol Spectr; 2022 Aug; 10(4):e0124722. PubMed ID: 35856710 [TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant. Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006 [TBL] [Abstract][Full Text] [Related]
31. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial. Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE; Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099 [TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China. Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960 [TBL] [Abstract][Full Text] [Related]
34. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Piernas C; Patone M; Astbury NM; Gao M; Sheikh A; Khunti K; Shankar-Hari M; Dixon S; Coupland C; Aveyard P; Hippisley-Cox J; Jebb SA Lancet Diabetes Endocrinol; 2022 Aug; 10(8):571-580. PubMed ID: 35780805 [TBL] [Abstract][Full Text] [Related]
35. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. MacIntyre CR; Costantino V; Trent M Vaccine; 2022 Apr; 40(17):2506-2513. PubMed ID: 33958223 [TBL] [Abstract][Full Text] [Related]
36. COVID-19 in City Council Civil Servants, 1 March 2020-31 January 2023: Risk of Infection, Reinfection, Vaccine Effectiveness and the Impact of Heterologous Triple Vaccination. Cegolon L; Larese Filon F Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543888 [No Abstract] [Full Text] [Related]
37. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial. Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE; Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140 [TBL] [Abstract][Full Text] [Related]
38. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021. Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273 [TBL] [Abstract][Full Text] [Related]
39. Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England. Chen DT; Copland E; Hirst JA; Mi E; Dixon S; Coupland C; Hippisley-Cox J BMC Med; 2024 Jun; 22(1):237. PubMed ID: 38858672 [TBL] [Abstract][Full Text] [Related]